Clinical impact of bisoprolol versus carvedilol in patients undergoing femoropopliteal stenting

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 7, 2014, Pages 691-702

  Soga, Yoshimitsu ^a   Iida, Osamu ^b   Suzuki, Kenji ^c   Hirano, Keisuke ^d   Kawasaki, Daizo ^e   Shintani, Yoshiaki ^f   Suematsu, Nobuhiro ^g   Yamaoka, Terutoshi ^h   Tsuchiya, Taketsugu ⁱ   Miyashita, Yusuke ^j   Okazaki, Shinya ^k   Shinozaki, Norihiko ^l   Takahashi, Hiroki ^m  

^a KOKURA MEMORIAL HOSPITAL   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c Sendai Kosei Hospital   (Japan)

^d SAISEIKAI YOKOHAMASHI TOBU HOSPITAL   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f Shin Koga Hospital   (Japan)

^g FUKUOKA RED CROSS HOSPITAL   (Japan)

^h MATSUYAMA RED CROSS HOSPITAL   (Japan)

ⁱ KANAZAWA MEDICAL UNIVERSITY   (Japan)

^j SHINSHU UNIVERSITY   (Japan)

^k JUNTENDO UNIVERSITY HOSPITAL   (Japan)

^l TOKAI UNIVERSITY HOSPITAL   (Japan)

^m YAMAGATA UNIVERSITY   (Japan)

more..

Author keywords

Beta blocker; Endovascular therapy; Femoropopliteal disease; Stent

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARBAZOLE DERIVATIVE; CARVEDILOL; PROPANOLAMINE DERIVATIVE;

AGED; COMPARATIVE STUDY; FEMALE; FEMORAL ARTERY; FOLLOW UP; HUMAN; JAPAN; MALE; PATHOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STENT; TREATMENT OUTCOME;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; BISOPROLOL; CARBAZOLES; FEMALE; FEMORAL ARTERY; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROPANOLAMINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 84905169449     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.21121     Document Type: Article

References (28)

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC Working Group: Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC). J Vasc Surg, 2007; 45 Suppl S: S5-67
2. Paravastu SC, Mendonca DA, da Silva A: Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg, 2009; 38: 66-70
3. Radack K, Deck C: Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med, 1991; 151: 1769-1776
4. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S; REACH Registry Investigators: One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA, 2007; 297: 1197-1206
5. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation, 1994; 9: 1765-1773
6. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet, 1999; 353: 9-13
7. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651-1658
8. Freemantle N, Cleland J, Young P, Mason J, Harrison J: beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ, 1999; 318: 1730-1737
9. Carlberg B, Samuelsson O, Lindholm LH: Atenolol in hypertension: is it a wise choice? Lancet, 2004 6-12; 364: 1684-1689
10. Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 2005; 366: 1545-1553
11. Kohro T, Hayashi D, Yamazaki T, Nagai R; JCAD Investigators: Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. Circ J, 2010; 74: 962-969
12. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, Koppensteiner R, Minar E, Schillinger M: Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv, 2009; 74: 1090-1095
13. Schillinger M, Sabeti S, Loewe C, Dick P, Amighi J, Mlekusch W, Schlager O, Cejna M, Lammer J, Minar E: Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med, 2006; 354: 1879-1888
14. Zeller T, Tiefenbacher C, Steinkamp HJ, Langhoff R, Wittenberg G, Schlüter M, Buergelin K, Rastan A, Krumsdorf U, Sixt S, Schulte CL, Tübler T, Krankenberg H: Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). J Endovasc Ther, 2008; 15: 390-398
15. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Jaff MR; RESILIENT Investigators: Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv, 2010; 3: 267-276
16. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, Loewe C, Cejna M, Lammer J, Minar E: Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation, 2007; 115: 2745-2749
17. Wellstein A, Palm D, Belz GG, Butzer R, Polsak R, Pett B: Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to betaadrenoceptor occupancy. Eur Heart J, 1987; 8 Suppl M: 3-8
18. Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, Böhm M: Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol, 2000; 36: 466-471
19. Beattie K, Phadke G, Novakovic J: Carvedilol. Profiles Drug Subst Excip Relat Methodol, 2013; 38: 113-157
20. Lancaster SG, Sorkin EM: Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs, 1988; 36: 256-285
21. Dorow P, Bethge H, Tönnesmann U: Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol, 1986; 31: 143-147
22. Chatterjee SS: The cardioselective and hypotensive effects of bisoprolol in hypertensive asthmatics. J Cardiovasc Pharmacol, 1986; 8 Suppl 11: S74-77
23. Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L, Weinberg A, Faries PL, Nowygrod R, Kent KC: Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000. J Vasc Surg, 2004; 39: 1200-1208
24. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM: National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg, 2009; 50: 54-60
25. Rowe VL, Lee W, Weaver FA, Etzioni D: Patterns of treatment for peripheral arterial disease in the United States: 1996-2005. J Vasc Surg, 2009; 49: 910-917
26. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation, 2006; 113: e463-654
27. Lainscak M, Podbregar M, Kovacic D, Rozman J, von Haehling S: Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med, 2011ct; 105 Suppl 1: S44-49
28. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators: Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv, 2011; 4: 495-504